UCIBIO is organized in 8 RESEARCH GROUPS (RG) with different but complementary backgrounds that reflect UCIBIO’s research strengths: STRUCTURAL MOLECULAR BIOLOGY (SMB), MOLECULAR MICROBIOLOGY & GENOMICS (MMG), THEORETICAL & COMPUTATIONAL BIOCHEMISTRY (TCB), TOXICOLOGY (TOXI), DRUGS TARGETS & BIOMARKERS (DTB), NANOIMMUNOTECH (NIT), BIOENGINEERING (BENG) and MEDICINAL TECHNOLOGY (MEDTECH).
The expertise from each RG provides the competencies to carry out research work towards common objectives that are defined in 4 THEMATIC LINES of action:
TL1- BIOLOGICAL & BIOMOLECULAR INTERACTIONS
TL2- DIAGNOSTICS, DRUG DISCOVERY & DEVELOPMENT
TL3- SAFETY in HUMAN & ENVIRONMENTAL HEALTH
The TLs focus areas and RGs strengths and synergies allow addressing complex problems from different but complementary angles, using both fundamental and applied perspectives.
Within TL1, a major goal is to understand biomolecular mechanisms, from primary processes of molecular recognition to interaction networks in and between living cells to expand our knowledge on cellular functions and molecular mechanisms of disease. Within TL2, new candidate molecules are identified and optimized to subsequently enter preclinical evaluation in dedicated drug discovery projects. The identification of new biomarkers allied with the design and production of nano-devices will ensure translation into innovative health technologies for new diagnosis and therapies. TL3 is pivotal to all scientific aspects addressed by UCIBIO's research program, and its main focus is an undisputed main challenge for industry, consumers, regulatory entities and academia. Finally, within TL4, basic and applied research in the field of Bioengineering explores the combination of nano- and microtechnologies to create devices for nanomedicine and innovative therapies, as well as applications in Industrial and Environmental Biotechnology (biopolymers production from industrial by-products) & Blue Biotechnology.